At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
Gemcitabine, local deliverydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas
In Brief
A Phase 1 clinical trial evaluating Gemcitabine, local delivery for Pancreatic Cancer. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
A dose escalation, safety study of local (intra-arterially) delivered gemcitabine to the pancreas using the RenovoCath R120 catheter to determine the maximum tolerated dose.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartMar 2015
Primary CompletionSep 2016
TodayJul 2026
First PostedSep 11, 2014
Enrollment StartMar 1, 2015
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.8 years ago
Interventions
Gemcitabine, local deliverydrug
Intra-arterial targeted drug delivery